Compare Aurobindo Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs TORRENT PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA TORRENT PHARMA AUROBINDO PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 10.5 77.4 13.6% View Chart
P/BV x 1.9 9.2 21.2% View Chart
Dividend Yield % 0.5 0.7 81.7%  

Financials

 AUROBINDO PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
TORRENT PHARMA
Mar-19
AUROBINDO PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs8301,964 42.3%   
Low Rs5271,245 42.3%   
Sales per share (Unadj.) Rs333.9453.4 73.6%  
Earnings per share (Unadj.) Rs40.425.8 156.5%  
Cash flow per share (Unadj.) Rs51.862.3 83.1%  
Dividends per share (Unadj.) Rs2.5017.00 14.7%  
Dividend yield (eoy) %0.41.1 34.8%  
Book value per share (Unadj.) Rs237.1279.2 84.9%  
Shares outstanding (eoy) m585.91169.22 346.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.03.5 57.4%   
Avg P/E ratio x16.862.2 27.0%  
P/CF ratio (eoy) x13.125.8 50.9%  
Price / Book Value ratio x2.95.7 49.8%  
Dividend payout %6.265.9 9.4%   
Avg Mkt Cap Rs m397,569271,513 146.4%   
No. of employees `00017.913.6 131.3%   
Total wages/salary Rs m25,84914,038 184.1%   
Avg. sales/employee Rs Th10,956.95,642.6 194.2%   
Avg. wages/employee Rs Th1,447.71,032.4 140.2%   
Avg. net profit/employee Rs Th1,324.3320.9 412.7%   
INCOME DATA
Net Sales Rs m195,63676,728 255.0%  
Other income Rs m1,553571 272.3%   
Total revenues Rs m197,18977,299 255.1%   
Gross profit Rs m39,51919,831 199.3%  
Depreciation Rs m6,6806,177 108.1%   
Interest Rs m2,6265,038 52.1%   
Profit before tax Rs m31,7679,187 345.8%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-881-3,570 24.7%   
Tax Rs m7,2691,254 579.9%   
Profit after tax Rs m23,6454,363 541.9%  
Gross profit margin %20.225.8 78.2%  
Effective tax rate %22.913.6 167.7%   
Net profit margin %12.15.7 212.5%  
BALANCE SHEET DATA
Current assets Rs m153,64550,375 305.0%   
Current liabilities Rs m120,42951,653 233.1%   
Net working cap to sales %17.0-1.7 -1,019.5%  
Current ratio x1.31.0 130.8%  
Inventory Days Days13592 146.8%  
Debtors Days Days6468 93.3%  
Net fixed assets Rs m103,90983,648 124.2%   
Share capital Rs m586846 69.2%   
"Free" reserves Rs m138,32246,397 298.1%   
Net worth Rs m138,90847,244 294.0%   
Long term debt Rs m1,80039,129 4.6%   
Total assets Rs m264,544141,209 187.3%  
Interest coverage x13.12.8 463.8%   
Debt to equity ratio x00.8 1.6%  
Sales to assets ratio x0.70.5 136.1%   
Return on assets %9.96.7 149.2%  
Return on equity %17.09.2 184.3%  
Return on capital %23.812.3 193.2%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31622,103 440.3%   
Fx outflow Rs m40,5895,522 735.1%   
Net fx Rs m56,72716,581 342.1%   
CASH FLOW
From Operations Rs m16,22017,981 90.2%  
From Investments Rs m-28,768-2,413 1,192.3%  
From Financial Activity Rs m19,191-13,145 -146.0%  
Net Cashflow Rs m6,6562,380 279.7%  

Share Holding

Indian Promoters % 54.1 71.5 75.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 7.0 113.2%  
FIIs % 27.7 12.6 219.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 8.8 115.9%  
Shareholders   69,601 26,511 262.5%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ABBOTT INDIA  ALKEM LABORATORIES  AJANTA PHARMA  PFIZER  ALEMBIC PHARMA  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 1,266 Points; Nifty Ends Above 9,100 Mark(Closing)

Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Related Views on News

DIVIS LABORATORIES at All Time High; BSE HEALTHCARE Index Up 4.4% (Market Updates)

Apr 9, 2020 | Updated on Apr 9, 2020

DIVIS LABORATORIES share price has hit an all time high at Rs 2,290 (up 5.7%). The BSE HEALTHCARE Index is up by 4.4%. Among the top gainers in the BSE HEALTHCARE Index today are DIVIS LABORATORIES (up 5.7%) and ABBOTT INDIA (up 5.3%). The top losers include DR. LAL PATHLABS LTD (down 0.8%) and THYROCARE TECHNOLOGIES (down 4.0%).

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

A Safe Stock to Lockdown Now(The 5 Minute Wrapup)

Apr 2, 2020

The market crashc has made strong, established brands attractive. Here's a stock to make the most of this opportunity...

The Insiders See a Buying Opportunity in These Smallcaps Amid Coronavirus Outbreak(Profit Hunter)

Mar 31, 2020

The promoters are buying these smallcaps amid the coronavirus outbreak.

How to Identify a Market Rebound(Fast Profits Daily)

Mar 27, 2020

This very useful indicator can spot a market bottom.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Apr 9, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS